Fig. 7: TACC1v25 inhibits the tumour growth in vivo.

The weight and volume of tumours in the Lenti-TACC1v25-Cal27 group are significantly less than those in the Lenti-NC-Cal27 group (N = 5). In Lenti-TACC1v25-Fadu group, weight is significantly decreased, but there is no significant change in tumour volume. ^*P < 0.05.